Modlin et al., 2005 - Google Patents

Current status of gastrointestinal carcinoids

Modlin et al., 2005

View HTML
Document ID
12947491258578886086
Author
Modlin I
Kidd M
Latich I
Zikusoka M
Shapiro M
Publication year
Publication venue
Gastroenterology

External Links

Snippet

Gastrointestinal (GI) carcinoids are ill-understood, enigmatic malignancies, which, although slow growing compared with adenocarcinomas, can behave aggressively. Carcinoids are classified based on organ site and cell of origin and occur most frequently in the GI (67%) …
Continue reading at www.gastrojournal.org (HTML) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/574—Immunoassay; Biospecific binding assay for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions

Similar Documents

Publication Publication Date Title
Modlin et al. Current status of gastrointestinal carcinoids
Hofland et al. Advances in the diagnosis and management of well-differentiated neuroendocrine neoplasms
Modlin et al. Carcinoid tumors of the stomach
Schindl et al. Is the new classification of neuroendocrine pancreatic tumors of clinical help?
Kulke et al. NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas
O'Grady et al. Pancreatic neuroendocrine tumours
LÄUFFER et al. Current status of gastrointestinal carcinoids
Caplin et al. Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids
Modlin et al. Priorities for improving the management of gastroenteropancreatic neuroendocrine tumors
Scherübl et al. Neuroendocrine tumors of the small bowels are on the rise: Early aspects and management
Pinchot et al. Carcinoid tumors
Odori et al. GPR119 expression in normal human tissues and islet cell tumors: evidence for its islet-gastrointestinal distribution, expression in pancreatic beta and alpha cells, and involvement in islet function
Mandair et al. Colonic and rectal NET's
Modlin et al. The archaic distinction between functioning and nonfunctioning neuroendocrine neoplasms is no longer clinically relevant
Effraimidis et al. Multiple endocrine neoplasia type 1 (MEN-1) and neuroendocrine neoplasms (NENs)
Brandi et al. Multiple endocrine neoplasia type 1
Galofré et al. Consensus on the management of advanced medullary thyroid carcinoma on behalf of the Working Group of Thyroid Cancer of the Spanish Society of Endocrinology (SEEN) and the Spanish Task Force Group for Orphan and Infrequent Tumors (GETHI)
Åkerström et al. Surgical aspects of neuroendocrine tumours
Abraham et al. Endoscopic management of a primary duodenal carcinoid tumor
Janiak et al. Insulin, insulin-like growth factor 1 and insulin-like growth factor binding protein 3 serum concentrations in patients with adenomatous colon polyps
Modlin et al. Carcinoid tumors
Mathew et al. Carcinoid Tumors of the Gastrointestinal Tract
Modlin et al. The Current Status of Gastroenteropancreatic Neuroendocrine Tumors
Brighi The role of MGMT promoter methylation as a predictive factor for temozolomide-based treatment in neuroendocrine neoplasms: a prospective observational study.
Buddhavarapu et al. Metastatic Insulinoma: A Case of Conversion from a Non-Functional Neuroendocrine Tumor